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Abstract: Atypical meningioma represent an intermediary group between the benign 
meningioma (grade I) and anaplastic meningioma (grade III), and are known for high 
recurrence rate and short life expectancy. After modification of the classification World 
Health Organization in 2007, subsequent studies have tried to find prognostic factors for 
recurrence and survival, which are inconstant from author to author. This paper aims to 
present a short review of the most important prognostic factors in atypical meningioma. 
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Introduction 
Atypical meningioma (AM) represent an 
intermediate risk group between benign 
(grade I) and anaplastic meningioma (grade 
III), being known for their tendency to relapse 
after the surgery (42, 54, 66) and increased 
morbidity and mortality (24, 37, 54, 63). 
The rarity of AM cases and the inconsistent 
histological criteria in time regarding their 
definition led to the difficult understanding of 
the management of these types of tumours, 
especially of the prognostic factors (2, 10, 20, 
40, 43, 47). Moreover, in recent years it has 
been noticed an increase in the number of AM 
diagnostics (13, 48) and that is why, in view of 
an adequate management, it is necessary to 
clarify the factors of prognostic in AM.  
 
Incidence 
Intracranial meningiomas represent about 
one third of the primary brain tumours (13, 
34), being the most frequent intracranial 
primary benign tumours (5, 7, 31). Among 
them, AM represents about 4.7-7.2% of all 
meningioma diagnoses (33). After introducing 
the classifications of World Health 
Organization (WHO) from 2000 and 2007, the 
percentage of AM increased to 20-30% among 
all the meningiomas (47, 48, 65). Willis et al., 
in a study on 314 patients for a period of ten 
years (1994-2003), concluded that if in 
agreement with WHO grading system (1993) 
AM represented 5-7%, according to the new 
criteria WHO (2000), they represented 20.4% 
(65). 
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The anatomo-pathological evolution of AM 
The existence of AM and malign 
meningioma was recognized from 1938, when 
Cushing and Eisenhardt reported a type of 
meningioma with mean survival rate of 2.5 
years (63). The concept of “atypical grade II 
meningioma” was introduced for the first time 
in 1985 by Professor Juha Jääskeläinen from 
Finland (25).  
In 1990, Mayo clinic group suggested a set 
of criteria for AM, where the absence of 
anaplasia, an important predicting factor for 
recurrence was the cerebral invasion (53). 
Three years later, in 1993, WHO included AM 
(grade II) as intermediary category between 
the benign meningioma (grade I) and 
anaplastic or malign meningioma (grade III). 
Nevertheless, in 1993 the criteria WHO were 
not implemented at large scale (48).  
Even though Cushing recognized since the 
1930s the malign potential of meningiomas 
(11), no uniform system of classification was 
accepted until 2000, when the classification 
WHO became more objective and 
reproducible (34). It was followed by the 
revision WHO in 2007, when the criteria of 
brain invasion became additional criterion in 
AM, even in the absence of anaplasia or atypia 
(49).  
In 2016, WHO upgraded the classification 
of meningiomas from 2007 (33). According to 
this new classification (32), based on three 
histological grades, AM were divided into: 
benign meningioma (grade I), atypical 
meningioma (grade II) and malignant 
meningioma (grade III).  
Currently, the criteria of diagnostic for AM 
are: clear or chordoid cell histology, brain 
infiltration, 4 to 19 mitoses per 10 high-power 
fields, or 3 or more of the following: increased 
cellularity, necrosis, small cell change, 
prominent nucleoli and “sheetlike” growth 
(33). The classification WHO of meningioma 
from 2016 reinforced “brain infiltration” as a 
stand-alone histological feature for AM (32, 
62).  
Factors of prognostic in AM  
The factors of prognostic in AM can be 
divided into: demographic (age, gender), 
clinical, factors of prognostic related to the 
morphology of the tumour (location of 
tumour, tumour dimensions, anatomo-
pathological characteristics) and prognostic 
factors related to the degree of surgery 
resection (Table I). 
I. Demographic factors of prognostic (age, 
gender) 
Age. Current studies have proved that the 
age of the patient with AM can be considered 
a factor of prognostic related to the survival 
(14, 56, 68). Furthermore, some studies have 
proved that an increased age at diagnosis was 
a factor of poor prognostic for recurrence (3, 
4, 8, 9, 14, 18, 56, 68), some authors 
mentioning even the age > 65 as being the age 
limit for poor prognosis (28, 47).  
Zaher et al. has proved that age < 50 is a 
good factor of prognostic for overall survival 
(OAS) (68), and Durand et al. has found as 
well as a factor of good prognostic the age < 60 
(14). On the other hand, Aboukais et al. has 
not found any difference between progression-
free survival (PFS) in relation to the age at 
diagnostic (1). 
Gender. Unlike benign meningiomas that 
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seem rather linked to oestrogen levels and thus 
more frequent in women, AM have different 
gender demographics, mainly larger in men 
(19, 35, 64, 70). As for gender as factor of 
prognostic, the studies are inconsistent. If 
some authors consider that male gender 
represents a risk factor for a shorter survival 
(61), others have reported that on the contrary, 
female gender would represent a predicting 
factor for recurrence, having a relapse rate 
twice as bigger that in male gender (69). 
II. Clinic factors of prognostic (motor deficit, 
Karnofsky Performance Status Scale) 
Related to admission simptoms, Zhao et al. 
concluded that the neurologic deficit (paresis) 
can be considered a factor of poor prognostic, 
since these patients had a higher tendency to 
relapse than the patients with other symptoms 
(69). 
Also, the Karnofsky Performance Status 
Scale (KPS) was taken into account as factor of 
prognostic. Thus, Zhao et al. proved that the 
patients with KPS >80 presented a higher PFS 
comparing with the patients with KPS < 80 
(69).  
III. Factors of prognostic related to the 
morphology of the tumour (tumour location, 
the dimensions of the tumour, the anatomo-
pathological characteristics) 
Tumor location. AM at the level of the 
cerebral convexity was associated with a 
longest survival, and it was correlated with the 
total excision made in case of locating the 
tumour (45, 55, 68). On the other hand, 
parasagittal-falcine location of AM led to an 
increase of recurrence, probably because of the 
residual tumour along the superior sagittal 
sinus (61). 
Dimensions of the tumour. Another factor 
of prognostic that influences the survival was 
found the size of the tumour (12, 18). Garzon-
Muvdi et al. noticed that in tumour with 
dimensions between 50 and 100 mm there is a 
decrease of survival by the increase of 
morbidity and mortality (18). 
Anatomo-pathological characteristics. 
With the classification WHO in 2007, the 
relation between the histological grade of the 
meningioma and the outcome has become 
even stronger, studies on long series 
confirming it (22, 53). 
The proliferative activity of meningiomas 
is measured with Ki-67 labelling index (LI), 
considered as a potential instrument to 
establish the recurrence of meningiomas (22, 
26, 44). The Ki-67 index proved in a study as 
being the strongest distinguishing criterion 
between atypical and classical and anaplastic 
meningioma (29).   
Also, the immunohistochemical 
overstaining for MIB-1 antigen, CDK4, CDK6, 
p53, p16, p21, pRB protein, cyclin D1 and 
mitotic index were proved to be factors of 
prognostic, showing a statistically higher 
recurrence rate and also a shorter time of 
recurrence versus understaining (27, 58, 59, 
60). Among them, higher MIB-1 LI proved to 
be the strongest indicator for poor outcome in 
AM (16, 46, 47, 61). Also, other anatomo-
pathological and immunohistochemical 
factors with role of factors of prognostic were 
also discovered, mitosis and osteopontin (6, 
30). When mitosis is closer to 20 per 10 high-
power fields, it reflects biology of tumour more 
aggressive comparing with low mitosis (6). 
Osteopontin, a protein involved in tumour 
progression was proved to be correlated with 
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poor clinical outcome and as predictor of AM 
(30).  
IV. Factors of prognostic related to surgery 
resection  
The extent of surgery was reported as being 
the most important predictor of outcome in 
patients with meningiomas by reducing both 
the mortality and the recurrence (3, 14, 15, 19, 
20, 21, 23, 34, 38, 47, 53, 57, 67, 68). 
The extent of resection (Simpson grading) 
was proved to be a factor of prognostic also in 
respect to the OAS. Thus, survival proved to be 
significantly higher in patients with gross total 
resection (GTR) (that most authors consider 
to be Simpson grade 1, 2) than those with 
subtotal resection (STR) (Simpson grade 3, 4) 
(1, 14, 17, 20, 27, 36, 46, 68, 69). Also, studies 
have shown that PFS was better in patients 
with subtotal resection (Simpson grade 3, 4) 
comparing with biopsy only (Simpson grade 
5) (28, 45, 56, 68). 
On the other hand, Pasquier et al. 
concluded in their study that the extent of 
surgery resection was not a factor of 
prognostic for the meningiomas of grade II 
and III, but its statistic analysis was done on 
the whole group, without distinction between 
the grades (47). 
Related to the bone invasion of the 
meningioma, even though initially it was not 
accepted as factor of prognostic in AM (41), 
Gabeau-Lacet et al. and Ho et al. proved that it 
can be an important predictor of poor 
treatment outcome (17, 22).  
Prognostic 
Patients with AM have a poor prognosis 
and increased mortality, with a median 
survival rate lower than 2 years (33). Also, 
patients with secondary AM have a risk of 
recurrence three times higher (69) and a rate 
of death at 3-5 years twice as higher (50, 51, 52) 
and about 10-30% of the AM undergoing 
transformation to WHO grade III (39, 67).
TABLE I 
Prognostic factors in AM (recent studies) 
Year Author No. cases Prognostic factors for survivals Prognostic factors for recurrence 
2016 Endo (16) 45 Age, degree of resection, MIB1-LI Age, MIB1-LI 
2015 Zhao (69) 89* Degree of resection, KPS Paresis, secondary meningioma, 
female 
2014 Hammouche (20) 79 - Degree of resection 
2013 Aboukais (1) 167 - Degree of resection 
2013 Park (46) 83 Age Degree of resection MIB1-LI 
2013 Zaher (68) 44 Degree of resection, age Degree of resection 
2011 Mair (36) 114 - Degree of resection 
2010 Vranic (61) 86* Male, parasagittal-falcine location Brain invasion, parasagittal-falcine 
location, high mitotic index 
2009 Durand (14) 166 Degree of resection, age Degree of resection, age 
2009 Gabeau-Lacet (17) 47 Age, bone involvement Degree of resection, bone 
involvement 
2008 Pasqueir (47) 119* Age, KPS, high mitotic index KPS, high mitotic index 
*atypical and anaplastic meningioma 
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Conclusion  
Many of the factors of prognostic for 
survival or recurrence, as well as the resection 
extent, histopathological characteristics, age, 
gender or patient’s symptoms on admission 
remain still unclear and must be verified in 
larger cohorts. 
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